Canakinumab With Darbepoetin Alfa in PTs With Lower-Risk MDS Who Have Failed ESA

NCT04798339 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

13

Enrollment

OTHER

Sponsor class

Conditions

Myelodysplastic Syndromes

Interventions

DRUG: Canakinumab Injection
DRUG: Darbepoetin Alfa

Sponsor

H. Lee Moffitt Cancer Center and Research Institute

Collaborators

[object Object]